|Trade names||Healon, Provisc, Viscoat, Hyalgan, Euflexxa, Supartz, Gel-One|
|AHFS/Drugs.com||Multum Consumer Information|
|CompTox Dashboard (EPA)|
|(what is this?)|
Sodium hyaluronate is the sodium salt of hyaluronic acid. It is a glycosaminoglycan and long-chain polymer of disaccharide units of Na-glucuronate-N-acetylglucosamine. It can bind to specific receptors for which it has a high affinity.
Mechanism of action
Sodium hyaluronate functions as a tissue lubricant and is thought to play an important role in modulating the interactions between adjacent tissues. It forms a viscoelastic solution in water. Mechanical protection for tissues (iris, retina) and cell layers (corneal, endothelium, and epithelium) are provided by the high viscosity of the solution. Elasticity of the solution assists in absorbing mechanical stress and providing a protective buffer for tissues. In facilitating wound healing, it is thought that it acts as a protective transport vehicle, taking peptide growth factors and other structural proteins to a site of action. It is then enzymatically degraded and active proteins are released to promote tissue repair.
Adverse effects are relatively rare when used to treat the joints.
It is used to treat knee pain in patients with osteoarthritis who have not received relief from other treatments. It is injected into the joint capsule, to act as both a shock absorber and a lubricant for the joint. Thus sodium hyaluronate is used as a viscosupplement, administered through a series of injections into the knee, increasing the viscosity of the synovial fluid, which helps lubricate, cushion and reduce pain in the joint. It is generally used as a last resort before surgery and provides symptomatic relief, by recovering the viscoelasticity of the articular fluid, and by stimulating new production from synovial fluid. Use of sodium hyaluronate may reduce the need for joint replacement. Injections appear to increase in effectiveness over the course of four weeks, reaching a peak at eight weeks and retaining some effectiveness at six months, with greater benefit for osteoarthritis than oral analgesics. It may also be effective when used with the ankle joint.
Intraocular viscoelastic injection
It is used as an aid in ophthalmic surgery acting as aqueous and vitreous humor, e.g. in cataract extraction (intra- and extracapsular), intraocular lens implantation, corneal transplant, glaucoma filtration, and retina attachment surgery and in the treatment of dry eyes. In surgical procedures in the anterior segment of eyeball, instillation of sodium hyaluronate its viscoelasticity enables maintenance of a deep chamber during surgical manipulation since the solution does not flow out of the open anterior chamber, allowing for efficient manipulation with less trauma to the corneal endothelium and other surrounding tissues. Its viscoelasticity also helps to push back the vitreous face and prevent formation of a postoperative flat chamber. In posterior segment surgery, sodium hyaluronate serves as a surgical aid to gently separate, maneuver, and hold tissues. It creates a clear field of vision, facilitating intra-operative and post-operative inspection of the retina and photocoagulation.
Skin injections in plastic surgery
Sodium hyaluronate is injected to reduce wrinkles on the face. As of 2017, the FDA had approved 13 hyaluronate preparations as so called dermal fillers. They are also used as a filler of lips or in other parts of the body, though not FDA approved. The filling effect is temporary and lasts for about six months or longer in most people.
Topically applied sodium hyaluronate can facilitate the absorption of biomacromolecules, i.e. pharmaceuticals, and function like a nanocarrier. Its effects on skin depend on the hyaluronate formulation and skin health: In barrier-deficient skin it restricted the delivery of biomacromolecules to the stratum corneum and viable epidermis. In normal skin, low-molecular weight hyaluronate (5 kDa) enhanced penetration into the epidermis.
Transepidermal water loss increased by 55.5% with low-molecular weight, and was reduced by 28% with crosslinked resilient, and by 16% with HMW. The addition to skin creams became popular in the second millennium. Its efficacy against wrinkles has not been tested in clinical trials.
After instillation into the lung, higher molecular weight hyaluronate appears to persist longer in the lung but if > 215 kD there was poor lung penetration and mucociliary clearance. Hyaluronate could allow access to lymph nodes draining the pulmonary bed.
In the late 1970s and early 1980s the material was used with the brand names of Hylartin and Hylartin Vetused in human and veterinary clinical trials (race horses) to treat osteoarthritis. The first commercially sold sodium hyaluronate had been developed by Endre Alexander Balazs under the brand name of Healon, manufactured by Pharmacia AB in Sweden in 1980. In 1986, sodium hyaluronate was used as an intra-articular injection to treat osteoarthritis of the knee with the product Hyalart/Hyalgan by Fidia of Italy.
- Boucher WS, Letourneau R, Huang M, Kempuraj D, Green M, Sant GR, Theoharides TC (January 2002). "Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress". The Journal of Urology. 167 (1): 380–4. doi:10.1016/S0022-5347(05)65472-9. PMID 11743360.
- Jubb RW, Piva S, Beinat L, Dacre J, Gishen P (2003). "A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee". International Journal of Clinical Practice. 57 (6): 467–74. PMID 12918884.
- "Hyaluronate sodium: Indications, Side Effects, Warnings" (Web). Drugs.com. Drugs.com. 5 February 2014. Retrieved 25 February 2014.
- Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE (January 2015). "Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis". Annals of Internal Medicine. 162 (1): 46–54. doi:10.7326/M14-1231. PMID 25560713. S2CID 207538194.
- Mandl LA, Losina E (January 2015). "Relative efficacy of knee osteoarthritis treatments: are all placebos created equal?". Annals of Internal Medicine. 162 (1): 71–2. doi:10.7326/M14-2636. PMC 4545522. PMID 25560716.
- Puhl W, Scharf P (July 1997). "Intra-articular hyaluronan treatment for osteoarthritis". Annals of the Rheumatic Diseases. 56 (7): 441. doi:10.1136/ard.56.7.441. PMC 1752402. PMID 9486013.
- Karlsson J, Sjögren LS, Lohmander LS (November 2002). "Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study". Rheumatology. 41 (11): 1240–8. doi:10.1093/rheumatology/41.11.1240. PMID 12421996.
- Kotz R, Kolarz G (November 1999). "Intra-articular hyaluronic acid: duration of effect and results of repeated treatment cycles". American Journal of Orthopedics. 28 (11 Suppl): 5–7. PMID 10587245.
- Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE (June 2011). "Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis--meta-analysis". Osteoarthritis and Cartilage. 19 (6): 611–9. doi:10.1016/j.joca.2010.09.014. PMID 21443958.
- Salk RS, Chang TJ, D'Costa WF, Soomekh DJ, Grogan KA (February 2006). "Sodium hyaluronate in the treatment of osteoarthritis of the ankle: a controlled, randomized, double-blind pilot study". The Journal of Bone and Joint Surgery. American Volume. 88 (2): 295–302. doi:10.2106/JBJS.E.00193. PMID 16452740.
- Shimmura S, Ono M, Shinozaki K, Toda I, Takamura E, Mashima Y, Tsubota K (November 1995). "Sodium hyaluronate eyedrops in the treatment of dry eyes". The British Journal of Ophthalmology. 79 (11): 1007–11. doi:10.1136/bjo.79.11.1007. PMC 505317. PMID 8534643.
- "Healon (Sodium Hyaluronate)" [package insert]. (2002). Kalamazoo, Michigan: Pharmacia Corporation. (Web). RxList. (Updated 8 December 2004). RxList, Inc. Retrieved 25 February 2014.
- "Soft Tissue Fillers Approved by the Center for Devices and Radiological Health". U.S. Food and Drug Administration. 2015-07-27.
- Beasley KL, Weiss MA, Weiss RA (May 2009). "Hyaluronic acid fillers: a comprehensive review". Facial Plastic Surgery. 25 (2): 86–94. doi:10.1055/s-0029-1220647. PMID 19415575.
- "Filling in Wrinkles Safely". U.S. Food and Drug Administration. 2016-12-20.
- Wickens JM, Alsaab HO, Kesharwani P, Bhise K, Amin MC, Tekade RK, Gupta U, Iyer AK (April 2017). "Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy". Drug Discovery Today. 22 (4): 665–680. doi:10.1016/j.drudis.2016.12.009. PMC 5413407. PMID 28017836.
- Witting M, Boreham A, Brodwolf R, Vávrová K, Alexiev U, Friess W, Hedtrich S (May 2015). "Interactions of hyaluronic Acid with the skin and implications for the dermal delivery of biomacromolecules". Molecular Pharmaceutics. 12 (5): 1391–401. doi:10.1021/mp500676e. PMID 25871518.
- Sundaram H, Mackiewicz N, Burton E, Peno-Mazzarino L, Lati E, Meunier S (April 2016). "Pilot Comparative Study of the Topical Action of a Novel, Crosslinked Resilient Hyaluronic Acid on Skin Hydration and Barrier Function in a Dynamic, Three-Dimensional Human Explant Model". Journal of Drugs in Dermatology. 15 (4): 434–41. PMID 27050698.
- Stukin S (27 August 2009). "Makeup gets in on the anti-aging craze". The LA Times.
- Kuehl C, Zhang T, Kaminskas LM, Porter CJ, Davies NM, Forrest L, Berkland C (June 2016). "Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation". Molecular Pharmaceutics. 13 (6): 1904–14. doi:10.1021/acs.molpharmaceut.6b00069. PMC 5200957. PMID 27157508.
- Hargittai M, Hargittai I, Balazs EA (2011). History of Hyaluroan Science: From Basic Science to Clinical Applications. 2. Pubmatrix. ISBN 978-0-9820350-4-7.
- "Fidia Farmaceutici S.p.A. to Distribute and Promote HYALGAN® (sodium hyaluronate) for Treatment of Osteoarthritis". Fidia Pharma. 26 September 2011. Archived from the original on 27 July 2014.